Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
12,834.00    -520.00 (-3.89%)
Bid:
12,910.00
Ask:
12,920.00
Spread: 10.00 (0.077%)
Market Cap: £199.04b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Stabilisation Notice

10 Jun 2021 11:32

RNS Number : 5097B
Morgan Stanley & Co. Int'l plc
10 June 2021
 

 

10 June 2021

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

AstraZeneca PLC

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 26 May 2021, Morgan Stanley & Co. International plc as Coordinating Stabilisation Manager (contact: Morgan Stanley Debt Syndicate - Daniel Shane; telephone:+44 20 7677-7070) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the EU Market Abuse Regulation (596/2014),as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:

AstraZeneca PLC

Guarantor (if any):

N/A

ISIN:

XS2347663507

Aggregate nominal amount:

EUR 800,000,000

Description:

EUR 800,000,000 0.375 per cent. Notes due 2029

Stabilisation Manager(s):

Morgan Stanley & Co. International plc

Goldman Sachs International

J.P. Morgan Securities plc

Offer price:

99.584%

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAFMMMTMTJBBBB
Date   Source Headline
3rd Apr 20233:00 pmRNSTotal Voting Rights
3rd Apr 20237:00 amRNSUltomiris recommended for NMOSD EU approval
30th Mar 20237:00 amRNSAstraZeneca completes KYM agreement for CMG901
27th Mar 202311:00 amRNSDirector/PDMR Shareholding
22nd Mar 202311:00 amRNSNotice of AGM
9th Mar 20237:00 amRNSImfinzi improved EFS in resectable lung cancer
8th Mar 202311:01 amRNSDirector/PDMR Shareholding
8th Mar 202311:00 amRNSDirector/PDMR Shareholding
6th Mar 20237:00 amRNSEnhertu DESTINY-PanTumor02 shows positive results
1st Mar 20233:00 pmRNSTotal Voting Rights
1st Mar 20237:00 amRNSAstraZeneca prices a $2.25bn bond offering
24th Feb 20236:15 pmRNSAstraZeneca prices a EUR1.5bn bond offering
24th Feb 20232:05 pmRNSAstraZeneca acquires CinCor for cardiorenal asset
24th Feb 202311:00 amRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSAstraZeneca enters agreement with KYM for CMG901
22nd Feb 20237:10 amRNSFiling of Form 20-F with SEC
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
1st Dec 20223:00 pmRNSBlock listing Interim Review
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.